Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib for preventing colorectal adenoma recurrence
NCT00282386Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 1999
- Primary completion
- Sep 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rofecoxib in Colorectal Adenoma (CRA), sponsored by Merck & Co.. Started Dec 1999; status: completed.
02
Drugs
rofecoxib
03
Conditions
Colorectal Adenoma (CRA)
Beyond the preview
Go deeper on NCT00282386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282386.